Sartorius Stedim: UBS upgrades stock

(CercleFinance.com) - UBS has upgraded its rating on Sartorius Stedim Biotech shares from "sell" to "buy", having increased its corresponding target price from 355 euros to 370 euros, with its new target price implying upside potential of 24% the pharmaceutical supplier's share.


"Predictability and sustainability of growth with high barriers of entry should prove to be attractive at 2x PEG in this environment of macro uncertainty," the broker said.


Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.